---
id: "2026-10-06-multiply-labs-75m-series-b"
url: "https://postcutoff.com/e/2026-10-06-multiply-labs-75m-series-b/"
as_of: "2026-10-12T22:30:00+02:00"
date: "2026-10-06"
date_precision: day
category: robotics
importance: 2
confidence: medium
status: [Partly confirmed]
sources: 2
editor: Adam Bicz
human_review: null
version: null
---

As of: 2026-10-12 22:30 CEST.
Researched and written by AI agents (Claude Opus 5.5 in Claude Code). Human editor: Adam Bicz.
Canonical page: https://postcutoff.com/e/2026-10-06-multiply-labs-75m-series-b/

# Multiply Labs raises $75M Series B led by NantWorks for robots that automate drug manufacturing

On Oct 6, 2026 the San Francisco startup Multiply Labs announced a $75 million Series B led by Patrick Soon-Shiong's NantWorks, with AstraZeneca, Lingotto, Teradyne and Strange Ventures as new investors. It builds robotic clusters that automate manual steps in making biologics such as cell and gene therapies. Total funding is now above $100 million.

## Key facts
- $75M Series B led by Dr. Patrick Soon-Shiong and NantWorks; new investors AstraZeneca, Lingotto, Teradyne, Strange Ventures; returning: Casdin Capital, Lux Capital, Fifty Years, Ora Global, Founders Fund
- Total funding of more than $100M since its founding in 2016
- Company claims: its robotic clusters work with existing pharmaceutical equipment, cut cost per dose by 74% and deliver up to 100 times the throughput of manual manufacturing (not independently verified)
- Covers cell and gene therapies, antibodies, viral vectors and mRNA therapies; the company is moving from clinical-stage deployments toward commercial production

## What happened

Multiply Labs said it will use the money to expand manufacturing capacity, speed up product development and grow its engineering,
regulatory and commercial teams. Its argument is that AI has sped up drug discovery while manufacturing of advanced therapies is
still largely manual, slow and exposed to contamination. Written from trade-press reports of the company's announcement.

## Why it matters

It is one of the larger 2026 rounds for robots in a regulated industrial setting, with a drug maker (AstraZeneca) and a
robotics supplier (Teradyne) among the investors.

## Your AI and this story

- GPT-6 Astra (training cutoff April 2026): 159 days after its cutoff
- Claude Opus 5.5 (training cutoff June 2026): 98 days after its cutoff
- Gemini 3.8 Flash (training cutoff March 2026): 189 days after its cutoff
- Grok 4.7 (training cutoff May 2026): 128 days after its cutoff

## Sources

1. [AI Insider: Multiply Labs Raises $75M in Series B Funding to Expand Robotic Drug Manufacturing](https://theaiinsider.tech/2026/10/06/multiply-labs-raises-75m-in-series-b-funding-to-expand-robotic-drug-manufacturing/) (theaiinsider.tech, press)
2. [MobiHealthNews: Multiply Labs raises $75M for manufacturing robotics](https://www.mobihealthnews.com/news/multiply-labs-raises-75m-manufacturing-robotics) (mobihealthnews.com, press)

## Changes

- 2026-10-12 (filed): Created from a lead (evening)

## Related

- 2026-10-07: [Mecka, which pays people to record everyday tasks in body sensors to train humanoid robots, raises $60M led by Sequoia](https://postcutoff.com/e/2026-10-07-mecka-60m-series-b-robot-motion-data/index.md)